CA-ASM-GLOBAL
17.4.2024 15:01:29 CEST | Business Wire | Press release
The Hong Kong Special Administrative Region Government, ASM Global and Kai Tak Sports Park Limited (KTSPL) — which is a subsidiary of New World Development — as part of a multiyear strategy, have announced a late winter testing period for Kai Tak marking the culmination of a near decade-long record $4 billion project creating the premiere sports, recreation, entertainment complex on Earth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417546819/en/
PLAY BALL – Kai Tak Sports Park, the largest and most ambitious sports-development and entertainment district in the world, is being managed by ASM Global. (Photo: Business Wire)
ASM Global, as the lead operator, has been on the ground in Hong Kong working for over five years supporting the design, programming and construction of Kai Tak Sports Park, featuring many of the world’s most advanced state-of-the-art venues and is now prepping for pre-opening activities in advance of 2025’s formal unveiling.
The project will include a 50,000-capacity main stadium with the theme “Pearl of the Orient” as its design inspiration and boasting a retractable roof and flexible pitch surface that can host a wide range of events in any weather, including major sports events, concerts and MICE events; a 10,000-capacity indoor sports arena that meets the standard of major international tournaments for a wide range of athletics, including basketball, tennis, gymnastics, family shows and other entertainment events; a 5,000-spectator, open-to-the-public sports ground for hosting school sports days, athletic meets, local football and rugby matches as well as team and athlete training sessions; and an outdoor recreation complex.
ASM Global’s President and CEO Ron Bension said, “ASM Global develops and builds spectacular venues and extraordinary entertainment districts throughout the world; but nothing compares to the scale, scope and state-of-the art innovation of Kai Tak.”
The Hong Kong site is part of ASM Global’s network of more than 400 venues around the world. The company works with major cultural and entertainment districts and venues and projects throughout the world, including Darling Harbour in Sydney, OVO Arena Wembley in London, AO Arena in Manchester and Desert Diamond in Arizona.
Officials said the expansive development will set the benchmark for multipurpose sports precincts worldwide, integrating the most advanced sports facilities with retail, wellness and community leisure spaces to create an urban oasis for the 7.4 million local community and millions of overseas visitors.
KTSPL, when awarded the contract for the design, build, construction and operation of the Kai Tak Sports Park, subsequently assembled an unparalleled project team comprising overseas and local experts in design; retail sales and marketing; construction led by Hip Hing; and ASM Global for project management, premium sales and programming.
The precinct is designed around the one-of-a-kind Kai Tak Sports Avenue. This indoor and outdoor pedestrian walk starts at Station Square and transports people completely through the immense site.
Throughout the complex will be restaurants, retail shops, jogging trails, a health and wellness center, as well as an international-standard bowling center with 40 lanes suitable for hosting international tournaments and a climbing wall on Sports Avenue.
ASM Global and KTSPL’s state-of-the-art environmentally conscious design decisions are critical to the project, intended to set and meet measurable goals to reduce impacts on the planet and champion dynamic programs for the longevity and well-being of the local community.
The focus of these sustainability efforts includes integration of photovoltaic panels on all major facilities, extensive green roofscapes and an expansive network of electric charging stations across the precinct. Smart city initiatives include an intelligent building and car management system, Wi-Fi hotspots, an indoor positioning system and mobile applications to facilitate precinct information booking of facilities and wayfinding.
Kai Tak Sports Park is expected to formally open in early 2025 and is one of the sports venues that will deliver events for the 2025 15th National Games of China that is being hosted in the Greater Bay Area.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417546819/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom